CAC
VINC

Cowen and Company’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Cowen and Company’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,200
Closed -$794K – 533
2020
Q3 		$794K Buy
+3,200
New +$651K 0.13% 104

Other funds holding VINC

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Cowen and Company's VINC Position: Q4 2020 in Review

Cowen and Company sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q4 2020, closing a stake of 3,200 shares — an estimated $794K sold.

Cowen and Company first reported a position in VINC in Q3 2020 and held it in 1 quarter. The position peaked at $794K in Q3 2020. 18 funds tracked by Wall St. Rank hold VINC as of Q4 2020.

  • Cowen and Company reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Cowen and Company sold 3,200 Vincerx Pharma, Inc. Common Stock shares in Q4 2020, an estimated $794K.
  • Cowen and Company first reported a position in Vincerx Pharma, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Cowen and Company's Vincerx Pharma, Inc. Common Stock position peaked at $794K in Q3 2020.
  • 18 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2020.

Based on Cowen and Company's 13F filing for Q4 2020, filed 8 Feb 2021.